Drug Profile
G 207
Alternative Names: G207; HSV G207Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Georgetown University Medical Center
- Developer MediGene Inc
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioma
Most Recent Events
- 01 Jan 2024 University of Alabama completes a phase I trial in Glioma (Recurrent, Second-line therapy or greater, In adolescents, In children) in USA (Intratumoral, Injection) (NCT02457845)
- 14 Sep 2021 Phase-I clinical trials in Glioma (In children, Recurrent, Second-line therapy or greater, In adults) in USA (Intratumoural)
- 12 Apr 2021 Efficacy and safety data from phase I trial in Glioma released by Treovir